相关实验视频
Updated: Jun 22, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
基于免疫检查点分子和免疫检查点抑制剂的免疫疗法在胃癌-叙述性审查中
Agata Poniewierska-Baran1,2,3, Karolina Sobolak4, Paulina Niedźwiedzka-Rystwej1,2
1Center of Experimental Immunology and Immunobiology of Infectious and Cancer Diseases, University of Szczecin, 71-417 Szczecin, Poland.
胃癌 (GC) 是具有侵略性和转移性的. 本综述探讨了免疫检查点抑制剂 (ICPI),针对编程死亡1/编程死亡连接体1 (PD-1/PD-L1) 和其他用于GC免疫治疗的分子.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症研究 癌症研究
背景情况:
- 胃癌 (GC) 是一种高度攻击性的恶性瘤,是全球癌症相关死亡的主要原因.
- 在GC中转移包括局部入侵,免疫逃避和遥远地点的殖民.
- 免疫检查点,如PD-1/PD-L1,CTLA-4和TIGIT,是免疫反应的关键调节者,并与瘤生长有关.
研究的目的:
- 探索免疫疗法在胃癌中的作用.
- 在GC治疗中专注于免疫检查点分子 (ICPMs) 及其抑制剂.
- 总结正在进行的临床试验,研究ICPM作为GC中的治疗点.
主要方法:
- 这项研究是一种叙事性审查.
- 它研究了癌症免疫检查点的机制.
- 它综合了关于GC免疫疗法的当前临床试验的信息.
主要成果:
- 免疫检查点分子 (ICPMs) 在免疫和瘤细胞上表达,调节免疫反应.
- ICPM及其连接体之间的相互作用对免疫细胞功能至关重要,也是癌症免疫疗法的关键目标.
- 包括PD-1/PD-L1,CTLA-4和TIGIT在内的各种ICPM正在研究其在GC中的治疗潜力.
结论:
- 免疫检查点抑制剂代表了胃癌治疗的有希望的途径.
- 准ICPM提供了一种克服GC免疫逃避的策略.
- 进一步的研究和临床试验对于优化基于ICPM的胃癌疗法至关重要.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
相关概念视频
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...